Marotta (Italy) made a brief state-of-the-art presentation on the specific issue of phytotherapeutic compounds in chronic liver disease and, particularly, in hepatitis C virus (HCV)-related liver disease, highlighting the wealth of good basic scientific data on several compounds but the lack of solid and welldesigned clinical data for most of them. In particular, the erratic pharmacokinetics of sylimarine is one of the reasons for the growing lack of confidence in most clinicians embarking upon such studies of this compound, while the rare but severe side effects of TJ-compounds pose a threat to their future wide application in clinics of Western countries. On the contrary, although so far limited by its intravenous administration route, quality-controlled glycyrrhizin acid-based compounds (SNMCs) are backed up by a considerable amount of in vitro, in vivo and clinical data.
Given the worthwhile Japanese data (mostly from Professor Tarao), proving that a hyper-transaminasemic state is a predictor of higher HCC transformation during the year, such compounds may represent a unique therapeutic weapon in patients with established liver cirrhosis who are not amenable to interferon (IFN associated with either ribavirin or SNMC and that these preliminary suggestions of equipotency of the two arms are deserving of great attention. Professor Nandini from the Indian Research Council expressed the Council's utmost interest in the scientific and ethical regulation of the matter and called for a common ground for discussion. He also pointed out the importance of considering the cost of medication. The discussion which followed was very exciting 'Expert clinicians such as Professor Ferenci, a pioneer in sylimarine research in Austria, made the disappointing assertion that, given the low costs of natural compounds, firms could hardly devote any funds to such worthwhile and badly needed research.' Other researchers from India and Western countries emphasized the great need for such complementary compounds to fill the gaps in the present chemical treatments such as side effects and increasing costs. Professor Blum announced an ongoing SNMC study that he is pursuing at his institution. In summary, each of these CAM sessions affirmed a definitive role for validated and quality-controlled phyto-compounds, their potentially unique benefits including the likelihood of better compliance by patients and reduced cost. The mandatory task remains to conduct evidence-based clinical studies that support such expectations.
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Meeting Report no response to IFN. He also mentioned the even wider potential application of this compound in other cumbersome clinical conditions such as non-alcoholic steatohepatitis (NASH), especially when considering the ongoing search to obtain an optimal bioavailable oral formulation of SNMC. Professor Wang described the more than 2000 year experience of Traditional Chinese Medicine, pointing out the difficult practical inferences in modern clinical practice. He also presented interesting recent clinical data on Phyllantus amarus and oxymatrine in hepatitis B virus (HBV)-related liver disease and of shisandra and SNMC in HCV-related liver disease. The session was concluded with a comment by Professor Habibullah who introduced an extensive survey that he is conducting on CAM practices for liver disease in India with the aim of regulating such matters while pooling data amenable to multi-center studies.
Another 2hr workshop was dedicated to this challenging CAM topic the next day, chaired by an authoritative Indian opinion leader in hepatology, Professor B. N. Tandom. As the previous day's speakers had reported their experience and the state of the art in their own countries, Professor Acharya also gave us an update on ongoing research in India. In particular, he mentioned one double-blind study in which IFN was
